Fudan Universtiy Shanghai Cancer Centre
Welcome,         Profile    Billing    Logout  
 11 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hu, Chaosu
AK105-304, NCT04974398: A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
3
296
Canada, US, RoW
Penpulimab, cisplatin/carboplatin, gemcitabine, placebo
Akeso
Nasopharyngeal Carcinoma
02/26
12/26
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
NCT03866967: A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

Completed
2
130
RoW
AK105
Akeso, Akeso Tiancheng, Inc
Nasopharyngeal Carcinoma
03/21
03/24
BL-B01D1-204-02, NCT06437522: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting
2
46
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, PD-1 monoclonal antibody
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Head and Neck Squamous Cell Carcinoma
06/26
06/26
NCT06857279: A Phase II Clinical Study to Evaluate HLX43 in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting
2
90
RoW
HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3
Shanghai Henlius Biotech
Carcinoma of Head And/or Neck
10/27
07/28
NCT06006169: A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting
2
186
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, SI-B003
Sichuan Baili Pharmaceutical Co., Ltd.
Head and Neck Squamous Cell Carcinoma
10/25
10/25
Xu, Tingting
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Active, not recruiting
1/2
1410
Canada, US, RoW
SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT)
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
12/25
07/26
Yang, Youqi
No trials found
Hu, Chao-su
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hu, Chaosu
AK105-304, NCT04974398: A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
3
296
Canada, US, RoW
Penpulimab, cisplatin/carboplatin, gemcitabine, placebo
Akeso
Nasopharyngeal Carcinoma
02/26
12/26
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
NCT03866967: A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

Completed
2
130
RoW
AK105
Akeso, Akeso Tiancheng, Inc
Nasopharyngeal Carcinoma
03/21
03/24
BL-B01D1-204-02, NCT06437522: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting
2
46
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, PD-1 monoclonal antibody
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Head and Neck Squamous Cell Carcinoma
06/26
06/26
NCT06857279: A Phase II Clinical Study to Evaluate HLX43 in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting
2
90
RoW
HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3
Shanghai Henlius Biotech
Carcinoma of Head And/or Neck
10/27
07/28
NCT06006169: A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting
2
186
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, SI-B003
Sichuan Baili Pharmaceutical Co., Ltd.
Head and Neck Squamous Cell Carcinoma
10/25
10/25
Xu, Tingting
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Active, not recruiting
1/2
1410
Canada, US, RoW
SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT)
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
12/25
07/26
Yang, Youqi
No trials found
Hu, Chao-su
No trials found

Download Options